Overview

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in which healthy adult volunteers will receive BRII-196/BRII-198 or placebo and will be assessed for safety, tolerability, and pharmacokinetics.
Phase:
Phase 1
Details
Lead Sponsor:
Brii Biosciences Limited
Collaborator:
TSB Therapeutics (Beijing) CO.LTD